BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260122T190000
DTEND;TZID=Africa/Nairobi:20260122T203000
DTSTAMP:20260526T145545
CREATED:20251222T165215Z
LAST-MODIFIED:20260319T171500Z
UID:40753-1769108400-1769113800@kesho-kenya.org
SUMMARY:Cervical Cancer Prevention and Control In Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \n(CPD Accredited) \nDate & Time: 22nd January 2026 7 PM – 8:30 PM (EAT) \n\nModerator: Dr. Benjamin Elly Odongo\nObstetrician/Gynecologist & Gynaecologic Oncologist\, Senior Lecturer & Chairman\, Department of Obstetrics & Gynaecology\, Kenyatta University School of Health Sciences\n\nSpeakers: \nProf. Lucy Muchiri\nAssociate Professor in the Department of Human Pathology\, University of Nairobi’s School of Medicine\nTopic: Overview of the WHO 90-70-90 cervical cancer elimination strategy and implications for pathology services \nProf. Omu Anzala Professor of Virology and Immunology\, Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI – ICR)\, University of Nairobi\, Kenya\nTopic: HPV Vaccination in Kenya: Scientific Evidence\, Immunological Perspectives\, and Public Controversies \nDr. Richa Bansal Gynecological Oncologist and Robotic Surgeon\, Apollo Hospitals\, Navi Mumbai\, India\nTopic: Cervical Cancer Prevention and Advanced Treatment \nHighlights\nThis session examined cervical cancer through the lens of prevention\, highlighting it as one of the few cancers where elimination is both feasible and within reach. \nA central theme was the WHO 90-70-90 strategy\, which outlines a clear pathway to elimination through HPV vaccination\, screening and timely treatment. Achieving these targets could reduce cervical cancer incidence to below 4 cases per 100\,000 women\, effectively transforming it into a rare disease. \nThe discussion emphasized that cervical cancer is almost entirely driven by persistent HPV infection\, making it uniquely preventable through vaccination and early detection. Evidence shows that HPV vaccines are highly effective\, with strong and sustained protection against high-risk HPV types responsible for most cases. \nDespite this\, the burden remains disproportionately high in low- and middle-income settings\, including Kenya\, where gaps in screening coverage\, diagnostic capacity and referral pathways continue to limit early detection and timely treatment. \nThe role of pathology services emerged as critical\, forming the diagnostic backbone for screening programs and treatment decisions. Expanding HPV DNA testing\, strengthening laboratory systems and investing in workforce development were identified as key priorities for achieving national targets. \nAcross the session\, a consistent message emerged: cervical cancer is preventable and eliminating it will depend on scaling what already works. \nKey Takeaways \n\nCervical cancer is one of the few cancers where elimination is achievable.\nThe WHO 90-70-90 targets provide a clear\, evidence-based roadmap.\nHPV vaccination and screening are high-impact prevention strategies.\nStrengthening pathology and diagnostic capacity is essential to progress.\nClosing gaps in access and coverage is critical to achieving equitable outcomes.
URL:https://kesho-kenya.org/event/cervical-cancer-prevention/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/01/WhatsApp-Image-2026-01-20-at-9.44.15-AM-e1768910604384.jpeg
END:VEVENT
END:VCALENDAR